Bonus BioGroup Ltd.

TASE:BONS Stock Report

Market Cap: ₪184.5m

Bonus BioGroup Management

Management criteria checks 3/4

Bonus BioGroup's CEO is Shai Meretzki, appointed in Apr 2012, has a tenure of 12.75 years. directly owns 32.97% of the company’s shares, worth ₪60.83M. The average tenure of the management team and the board of directors is 7.5 years and 8.5 years respectively.

Key information

Shai Meretzki

Chief executive officer

₪2.0m

Total compensation

CEO salary percentagen/a
CEO tenure12.8yrs
CEO ownership33.0%
Management average tenure7.5yrs
Board average tenure8.5yrs

Recent management updates

Recent updates

We're Keeping An Eye On Bonus BioGroup's (TLV:BONS) Cash Burn Rate

Apr 01
We're Keeping An Eye On Bonus BioGroup's (TLV:BONS) Cash Burn Rate

Will Bonus BioGroup (TLV:BONS) Spend Its Cash Wisely?

Dec 11
Will Bonus BioGroup (TLV:BONS) Spend Its Cash Wisely?

We're Keeping An Eye On Bonus BioGroup's (TLV:BONS) Cash Burn Rate

Jun 14
We're Keeping An Eye On Bonus BioGroup's (TLV:BONS) Cash Burn Rate

Is Bonus BioGroup (TLV:BONS) In A Good Position To Deliver On Growth Plans?

Dec 13
Is Bonus BioGroup (TLV:BONS) In A Good Position To Deliver On Growth Plans?

Companies Like Bonus BioGroup (TLV:BONS) Are In A Position To Invest In Growth

Jun 26
Companies Like Bonus BioGroup (TLV:BONS) Are In A Position To Invest In Growth

Here's Why We're Not Too Worried About Bonus BioGroup's (TLV:BONS) Cash Burn Situation

Jan 28
Here's Why We're Not Too Worried About Bonus BioGroup's (TLV:BONS) Cash Burn Situation

Here's Why We're Not Too Worried About Bonus BioGroup's (TLV:BONS) Cash Burn Situation

Sep 15
Here's Why We're Not Too Worried About Bonus BioGroup's (TLV:BONS) Cash Burn Situation

Here's What Bonus BioGroup Ltd.'s (TLV:BONS) Shareholder Ownership Structure Looks Like

Mar 05
Here's What Bonus BioGroup Ltd.'s (TLV:BONS) Shareholder Ownership Structure Looks Like

What Kind Of Investors Own Most Of Bonus BioGroup Ltd. (TLV:BONS)?

Nov 19
What Kind Of Investors Own Most Of Bonus BioGroup Ltd. (TLV:BONS)?

CEO

Shai Meretzki (55 yo)

12.8yrs

Tenure

₪2,039,000

Compensation

Dr. Shai Meretzki, PhD is the Founder of Pluristem Therapeutics, Inc. and Bonus BioGroup Ltd (Formerly BoneUs Therapeutics Ltd). Dr. Meretzki founded the Bonus BioGroup Ltd. He has been the Chief Executive...

Leadership Team

NamePositionTenureCompensationOwnership
Joseph Rauch
Executive Chairman of the Board12.8yrs₪1.54mno data
Shai Meretzki
Founder12.8yrs₪2.04m32.97%
₪ 60.8m
Yoni Livne
Chief Financial Officer10.6yrs₪804.00k0.19%
₪ 348.1k
Dror David
Chief Operations Officer3.9yrs₪749.00kno data
Vered Kivity
Head of Regulatory Affairs & VP of Clinical Affairs4.4yrsno datano data

7.5yrs

Average Tenure

52yo

Average Age

Experienced Management: BONS's management team is seasoned and experienced (7.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Joseph Rauch
Executive Chairman of the Board12.8yrs₪1.54mno data
Shai Meretzki
Founder12.8yrs₪2.04m32.97%
₪ 60.8m
Malcolm Hoenlein
Member of Business Advisory Boardno datano datano data
Gil Shapira
Non-Executive Director12.8yrsno data0.61%
₪ 1.1m
Nimrod Rozen
Member of Scientific Advisory Boardno datano datano data
Yehuda Ullman
Member of Scientific Advisory Boardno datano datano data
Ephraim Tzur
Member of Scientific Advisory Boardno datano datano data
Benjamin Shafir
Independent Non-Executive Director4.3yrsno datano data
Margalit Assayag
Independent Non-Executive Director4.3yrsno datano data
Alon Ariel
Non-Executive Director4.3yrsno datano data
Or Shoshan
Member of Business Advisory Boardno datano datano data

8.5yrs

Average Tenure

65yo

Average Age

Experienced Board: BONS's board of directors are considered experienced (8.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/05 10:04
End of Day Share Price 2025/01/05 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Bonus BioGroup Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution